Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Yu

Orthopaedic Surgery of the Spine New Orleans, LA Medical Doctor

NPI 1891189130 CMS profile 1359391

1514 Jefferson Hwy, New Orleans, LA 70121

Open in the dashboard

General payments

$51,682

246 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Yu of New Orleans, LA is reported in the CMS Open Payments database as having received $51,682 across 246 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,519 41
2024 General $6,812 55
2023 General $4,043 33
2022 General $9,917 16
2021 General $10,828 64
2020 General $972 16
2019 General $4,591 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Yu
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Charles Yu were reported at $14,519. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Charles Yu Orthopaedic Surgery of the Spine median Middle half National median
2019 $4,591 $2,106 $337–$18,608 $163
2020 $972 $1,213 $156–$15,082 $114
2021 $10,828 $1,834 $271–$15,617 $132
2022 $9,917 $2,015 $320–$17,036 $149
2023 $4,043 $1,925 $336–$14,599 $160
2024 $6,812 $2,110 $341–$12,483 $164
2025 $14,519 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spine Wave, Inc. $13,675 22 payments
  2. Medical Device Business Services, Inc. $10,853 24 payments
  3. Globus Medical, Inc. $6,617 34 payments
  4. Medtronic, Inc. $4,849 49 payments
  5. Stryker Corporation $4,792 26 payments
  6. NuVasive, Inc. $4,537 36 payments
  7. DePuy Synthes Sales Inc. $1,483 24 payments
  8. Pinnacle, Inc $1,423 4 payments
  9. Medtronic USA, Inc. $801 4 payments
  10. Alphatec Spine, Inc $404 2 payments
  11. Other $2,248 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $21,084 78 payments
  2. Consulting Fee $17,977 8 payments
  3. Food and Beverage $10,308 153 payments
  4. Education $2,314 7 payments
Products named General payments · program years 2019–2025
  1. CONDUIT $9,324 18 payments
  2. SALVO SPINE SYSTEM Spinal Medical Device $8,739 4 payments
  3. XLIF $4,140 24 payments
  4. EVEREST SPINAL SYSTEM $2,744 14 payments
  5. UNID_PASS $2,442 25 payments
  6. Corbel $2,078 10 payments
  7. SPINAL IMPLANT $2,033 10 payments
  8. SALVO SPINE SYSTEM Spinal Medical Device $2,000 3 payments
  9. ALIF $1,970 6 payments
  10. EXCELSIUS GPS $1,742 8 payments
  11. Other $14,680 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

375

Median for Orthopedic Surgery: 203

Drug cost

$2,544

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 164 $1,288
Gabapentin Generic 75 $456
Pregabalin Generic 29 $286
Celecoxib Generic 16 $260
Meloxicam Generic 78 $185
Cyclobenzaprine Hcl Generic 13 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$149,168

Medicare's payments for the services billed

Medicare patients

215

Average age 72

Services billed

619

125 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 31%
Ischemic heart disease 30%
Diabetes 27%
Depression 27%
Osteoporosis 25%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record